hrcak mascot   Srce   HID

Pregledni rad

Pathophysiology of hormone-resistant prostate cancer

BORISLAV BELEV ; borislavbelev@gmail.com
TOMISLAV ŠIPIĆ

Puni tekst: engleski, pdf (1 MB) str. 387-392 preuzimanja: 551* citiraj
APA 6th Edition
BELEV, B. i ŠIPIĆ, T. (2014). Pathophysiology of hormone-resistant prostate cancer. Periodicum biologorum, 116 (4), 387-392. Preuzeto s https://hrcak.srce.hr/137761
MLA 8th Edition
BELEV, BORISLAV i TOMISLAV ŠIPIĆ. "Pathophysiology of hormone-resistant prostate cancer." Periodicum biologorum, vol. 116, br. 4, 2014, str. 387-392. https://hrcak.srce.hr/137761. Citirano 08.08.2020.
Chicago 17th Edition
BELEV, BORISLAV i TOMISLAV ŠIPIĆ. "Pathophysiology of hormone-resistant prostate cancer." Periodicum biologorum 116, br. 4 (2014): 387-392. https://hrcak.srce.hr/137761
Harvard
BELEV, B., i ŠIPIĆ, T. (2014). 'Pathophysiology of hormone-resistant prostate cancer', Periodicum biologorum, 116(4), str. 387-392. Preuzeto s: https://hrcak.srce.hr/137761 (Datum pristupa: 08.08.2020.)
Vancouver
BELEV B, ŠIPIĆ T. Pathophysiology of hormone-resistant prostate cancer. Periodicum biologorum [Internet]. 2014 [pristupljeno 08.08.2020.];116(4):387-392. Dostupno na: https://hrcak.srce.hr/137761
IEEE
B. BELEV i T. ŠIPIĆ, "Pathophysiology of hormone-resistant prostate cancer", Periodicum biologorum, vol.116, br. 4, str. 387-392, 2014. [Online]. Dostupno na: https://hrcak.srce.hr/137761. [Citirano: 08.08.2020.]

Sažetak
Androgen-deprivation therapy (ADT) has been for many years the cornerstone of metastatic prostate carcinoma (PC) treatment. It is very well documented that the majority of cancer cells in prostate gland remain androgen responsive what was the basis for androgen suppression in treatment. Nevertheless, after some time or sometimes initially, PCa cells become resistant to castration serum level of testosteron, because of some genetic and epigenetic changes that make them independent from hormone activation. There are two therories – the clonal theory and the adaptation theory of how some carcinoma cells become castration-resistant. It has been shown recently, that PCa cells can still use androgen receptor as a major signaling pathway, by activation of enzyme machinery or de novo production of androgen within the cells.

Ključne riječi
metastatic prostate cancer; androgen receptor (AR) castration-resistant prostate cancer (CRPC); androgen deprivation therapy (ADT)

Hrčak ID: 137761

URI
https://hrcak.srce.hr/137761

Posjeta: 694 *